FOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE
Akonni Biosystems
Kevin Banks, Ph.D.
301-698-0101 x232
kbanks@akonni.com
FREDERICK, MD. – January 5, 2010 – Akonni Biosystems, a molecular diagnostic (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced that Charles Daitch, Ph.D., CEO of Akonni Biosystems, will be presenting at the 2010 OneMedForumconference at the St. Francis Drake Hotel in San Francisco, CA on January 12, 2010. He will be speaking in the Private Companies track at 4:15 pm in Room 313/Mezzanine Level, with a 40‐minute break out session immediately following.
Akonni Biosystems was founded in 2003 and has over 20 patents issued with 13 others pending. The company’s core technology is based on work developed at Argonne National Laboratory and the Engelhardt Institute of Molecular Biology and utilizes geldrop array technologies optimized for developing medical applications. Supported by a series of government grants and contracts from NIH, CDC, DOE, DOD, NIJ, and NSF, the company has significantly advanced the original technology by improving the system’s capabilities from sample preparation to final result. Products in its near‐term pipeline include multiplex panel assays for detecting multidrug‐resistant tuberculosis, upper respiratory infections, encephalitis, and hospital‐acquired infections.
Akonni products are currently for research use only. Not for use in diagnostic procedures.
For more information please visit www.akonni.com.
© 2003-2024 Akonni Biosystems, Inc. All rights reserved. Terms and Conditions • Privacy Policy
TruDiagnosis Systems, TruDx Readers, TruArray Tests, TruTip Kits, Primers, Lysis and Binding Buffers, Wash Buffers and Elution Buffers: For Research Use Only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of a disease.
Based on its recent analysis of the microarrays in molecular diagnostics (MDx) market, Frost & Sullivan recognizes Akonni Biosystems with the 2017 North American New Product Innovation Award.
Akonni’s integrated MDx system, TruDiagnosis®, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis® is powered by TruArray®, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time.
Download: